Villalona-Calero Miguel A, Duan Wenrui, Zhao Weiqiang, Shilo Konstantin, Schaaf Larry J, Thurmond Jennifer, Westman Judith A, Marshall John, Xiaobai Li, Ji Jiuping, Rose Jeffrey, Lustberg Maryam, Bekaii-Saab Tanios, Chen Alice, Timmers Cynthia
Divisions of Medical Oncology (MAVC, WD, JR, ML, TBS) and Clinical Cancer Genetics (JAW), Department of Pathology (WZ, KS), Comprehensive Cancer Center (MAVC, WD, LJS, JT, TBS, CT), and Center for Biostatistics (LX), The Ohio State University , Columbus, OH ; Lombardi Cancer Center, Georgetown University , Washington, DC (JM); National Cancer Institute , Bethesda, MD (JJ, AC).
J Natl Cancer Inst. 2016 Feb 4;108(7). doi: 10.1093/jnci/djv437. Print 2016 Jul.
BRCA germline mutations are being targeted for development of PARP inhibitors. BRCA genes collaborate with several others in the Fanconi Anemia (FA) pathway. We screened cancer patients' tumors for FA functional defects then aimed to establish the safety/feasibility of administering PARP inhibitors as monotherapy and combined with a DNA-breaking agent.
Patients underwent FA functional screening for the presence (or lack) of tumor FancD2 nuclear foci formation on their archival tumor material, utilizing a newly developed method (Fanconi Anemia triple-stain immunofluorescence [FATSI]), performed in a Clinical Laboratory Improvement Amendments-certified laboratory. FATSI-negative patients were selected for enrollment in a two-arm dose escalation trial of veliparib, or veliparib/mitomycin-C (MMC).
One hundred eighty-five of 643 (28.7%) screened patients were FATSI-negative. Sixty-one received veliparib or veliparib/MMC through 14 dose levels. Moderate/severe toxicities included fatigue (DLT at veliparib 400mg BID), diarrhea, and thrombocytopenia. Recommended doses are 300mg BID veliparib and veliparib 200mg BID for 21 days following 10mg/m(2) MMC every 28 days. Six antitumor responses occurred, five in the combination arm (3 breast, 1 ovarian, 1 endometrial [uterine], and 1 non-small cell lung cancer). Two patients have received 36 and 60 cycles to date. BRCA germline analysis among 51 patients revealed five deleterious mutations while a targeted FA sequencing gene panel showed missense/nonsense mutations in 29 of 49 FATSI-negative tumor specimens.
FATSI screening showed that a substantial number of patients' tumors have FA functional deficiency, which led to germline alterations in several patients' tumors. Veliparib alone or with MMC was safely administered to these patients and produced clinical benefit in some. However, a better understanding of resistance mechanisms in this setting is needed.
BRCA种系突变正被作为聚腺苷二磷酸核糖聚合酶(PARP)抑制剂的研发靶点。BRCA基因在范可尼贫血(FA)通路中与其他几个基因协同作用。我们对癌症患者的肿瘤进行FA功能缺陷筛查,然后旨在确定PARP抑制剂作为单一疗法以及与一种DNA断裂剂联合使用的安全性/可行性。
利用一种新开发的方法(范可尼贫血三重染色免疫荧光法[FATSI]),在一个获得临床实验室改进修正案认证的实验室中,对患者存档的肿瘤材料进行肿瘤FancD2核灶形成情况(或有无)的FA功能筛查。FATSI阴性的患者被选入维利帕尼或维利帕尼/丝裂霉素-C(MMC)的双臂剂量递增试验。
643例接受筛查的患者中有185例(28.7%)为FATSI阴性。61例患者通过14个剂量水平接受了维利帕尼或维利帕尼/MMC治疗。中度/重度毒性包括疲劳(维利帕尼400mg每日两次时出现剂量限制性毒性)、腹泻和血小板减少。推荐剂量为维利帕尼300mg每日两次,以及在每28天给予10mg/m²MMC后,维利帕尼200mg每日两次,共21天。出现了6例抗肿瘤反应,联合治疗组有5例(3例乳腺癌、1例卵巢癌、1例子宫内膜癌[子宫癌]和1例非小细胞肺癌)。截至目前,2例患者分别接受了36个和60个周期的治疗。对51例患者进行的BRCA种系分析发现了5个有害突变,而一个靶向FA测序基因panel显示,49个FATSI阴性肿瘤标本中有29个存在错义/无义突变。
FATSI筛查显示,相当数量患者的肿瘤存在FA功能缺陷,这导致了部分患者肿瘤中的种系改变。维利帕尼单独或与MMC联合用药对这些患者安全有效,且在部分患者中产生了临床获益。然而,在此情况下需要更好地了解耐药机制。